Targeting the mTOR signaling network in cancer

Trends in Molecular Medicine

Volumn 13, Issue 10, 2007, Pages 433-442

  Chiang, Gary G ^a   Abraham, Robert T ^b  

^a BURNHAM INSTITUTE   (United States)

^b Wyeth ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AP 23573; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; SORAFENIB; TEMSIROLIMUS; TORISEL; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CARCINOGENESIS; CLINICAL TRIAL; DRUG TARGETING; FEEDBACK SYSTEM; HUMAN; NONHUMAN; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN KINASES; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 35348820823     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2007.08.001     Document Type: Review

References (87)

1. Wullschleger S., et al. TOR signaling in growth and metabolism. Cell 124 (2006) 471-484
2. Abraham R.T. PI 3-kinase related kinases: 'big' players in stress-induced signaling pathways. DNA Repair (Amst.) 3 (2004) 883-887
3. Guertin D.A., and Sabatini D.M. Defining the Role of mTOR in Cancer. Cancer Cell 12 (2007) 9-22
4. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 6 (2006) 729-734
5. Sarbassov D.D., et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
6. Bhaskar P.T., and Hay N. The two TORCs and Akt. Dev. Cell 12 (2007) 487-502
7. Plas D.R., and Thompson C.B. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24 (2005) 7435-7442
8. Jacinto E., et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6 (2004) 1122-1128
9. Sarbassov D.D., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14 (2004) 1296-1302
10. Guertin D.A., et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 11 (2006) 859-871
11. Gangloff Y.G., et al. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol. Cell. Biol. 24 (2004) 9508-9516
12. Murakami M., et al. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol. Cell. Biol. 24 (2004) 6710-6718
13. Jacinto E., et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127 (2006) 125-137
14. Shiota C., et al. Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev. Cell 11 (2006) 583-589
15. Yang Q., et al. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev. 20 (2006) 2820-2832
16. Hresko R.C., and Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 280 (2005) 40406-40416
17. Chiang G.G., and Abraham R.T. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J. Biol. Chem. 280 (2005) 25485-25490
18. Holz M.K., and Blenis J. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J. Biol. Chem. 280 (2005) 26089-26093
19. Zhang H.H., et al. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol. Cell 24 (2006) 185-197
20. Zeng Z., et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109 (2006) 3509-3512
21. Dann S.G., et al. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol. Med. 13 (2007) 252-259
22. Long X., et al. Rheb binds and regulates the mTOR kinase. Curr. Biol. 15 (2005) 702-713
23. Sancak Y., et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25 (2007) 903-915
24. Dong J., and Pan D. Tsc2 is not a critical target of Akt during normal Drosophila development. Genes Dev. 18 (2004) 2479-2484
25. Hahn-Windgassen A., et al. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J. Biol. Chem. 280 (2005) 32081-32089
26. Hsu Y.C., et al. Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature 445 (2007) 785-788
27. Kovacina K.S., et al. Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J. Biol. Chem. 278 (2003) 10189-10194
28. Vander Haar E., et al. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol. 9 (2007) 316-323
29. Oshiro N., et al. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J. Biol. Chem. 282 (2007) 20329-20339
30. Fonseca B.D., et al. PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J. Biol. Chem. 282 (2007) 24514-24524
31. Wang L., et al. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J. Biol. Chem. 282 (2007) 20036-20044
32. Schalm S.S., and Blenis J. Identification of a conserved motif required for mTOR signaling. Curr. Biol. 12 (2002) 632-639
33. Schalm S.S., et al. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr. Biol. 13 (2003) 797-806
34. Nojima H., et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J. Biol. Chem. 278 (2003) 15461-15464
35. Ellisen L.W. Growth control under stress: mTOR regulation through the REDD1-TSC pathway. Cell Cycle 4 (2005) 1500-1502
36. Byfield M.P., et al. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J. Biol. Chem. 280 (2005) 33076-33082
37. Nobukuni T., et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 14238-14243
38. Smith E.M., et al. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J. Biol. Chem. 280 (2005) 18717-18727
39. Findlay G.M., et al. A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling. Biochem. J. 403 (2007) 13-20
40. Shaw R.J., and Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 (2006) 424-430
41. Eng C. PTEN: one gene, many syndromes. Hum. Mutat. 22 (2003) 183-198
42. Cully M., et al. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6 (2006) 184-192
43. Luo J., et al. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4 (2003) 257-262
44. Broderick D.K., et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res. 64 (2004) 5048-5050
45. Campbell I.G., et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64 (2004) 7678-7681
46. Samuels Y., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
47. Sergina N.V., et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445 (2007) 437-441
48. Edinger A.L., et al. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res. 63 (2003) 8451-8460
49. Harrington L.S., et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166 (2004) 213-223
50. Shah O.J., et al. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14 (2004) 1650-1656
51. Zhang H., et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J. Clin. Invest. 117 (2007) 730-738
52. Manning B.D., et al. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev. 19 (2005) 1773-1778
53. Ma L., et al. Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev. 19 (2005) 1779-1786
54. O'Reilly K.E., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66 (2006) 1500-1508
55. Sun S.Y., et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65 (2005) 7052-7058
56. Skeen J.E., et al. Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell 10 (2006) 269-280
57. Fan Q.W., et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9 (2006) 341-349
58. Sarbassov D.D., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22 (2006) 159-168
59. Faivre S., et al. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5 (2006) 671-688
60. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297 (2002) 63-64
61. Mills G.B., et al. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10031-10033
62. Neshat M.S., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10314-10319
63. Podsypanina K., et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10320-10325
64. Yu K., et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer 8 (2001) 249-258
65. Margolin K., et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 104 (2005) 1045-1048
66. Galanis E., et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 23 (2005) 5294-5304
67. Bjornsti M.A., and Houghton P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4 (2004) 335-348
68. Oza A.M., et al. Molecular correlates associated with a Phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer. J. Clin. Oncol. 24 (2006) 3003
69. Tashiro H., et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 57 (1997) 3935-3940
70. Baak J.P., et al. Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression. Hum. Pathol. 36 (2005) 555-561
71. Hudes G., et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first line, poor risk patients with advanced renal cell carcinoma (adv RCC). J. Clin. Oncol. 24 (2006) LBA4
72. Yang H., and Kaelin Jr. W.G. Molecular pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: implications for oxygen sensing. Cell Growth Differ. 12 (2001) 447-455
73. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
74. Hudson C.C., et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22 (2002) 7004-7014
75. Laughner E., et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21 (2001) 3995-4004
76. Thomas G.V., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 12 (2006) 122-127
77. Brunn G.J., et al. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 15 (1996) 5256-5267
78. Knight Z.A., et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125 (2006) 733-747
79. Brugarolas J., and Kaelin Jr. W.G. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 6 (2004) 7-10
80. Hardie D.G., et al. AMP-activated protein kinase-development of the energy sensor concept. J. Physiol. 574 (2006) 7-15
81. Sanchez-Cespedes M., et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 62 (2002) 3659-3662
82. Schedin P., and Elias A. Multistep tumorigenesis and the microenvironment. Breast Cancer Res. 6 (2004) 93-101
83. Holash J., et al. Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents. Cancer Metastasis Rev. 25 (2006) 243-252
84. Guba M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8 (2002) 128-135
85. Phung T.L., et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10 (2006) 159-170
86. Liu M., et al. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. Cancer Res. 65 (2005) 5325-5336
87. de Visser K.E., et al. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6 (2006) 24-37